MPM Capital is a healthcare investment firm that focuses on early-stage ventures in the biotechnology, pharmaceuticals, and medical technology sectors. The company leverages its deep experience and network in the healthcare industry to identify and invest in promising life sciences companies, providing them with strategic guidance and capital to develop innovative therapies and technologies.

MPM BioImpact is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its world-class team and deep experience in scientific research, clinical development, and company-building, MPM BioImpact strives to power novel medical breakthroughs that transform patients’ lives. MPM BioImpact invests across the biotech landscape from early stage start-ups to public companies.

Clinical Ink

23andMe

Repare Therapeutics

Acceleron Pharma

Athersys

Humanigen

Nevro

Rhythm Pharmaceuticals

Syndax Pharmaceuticals

TCR2

TriNetX

Verastem Oncology

Harpoon Therapeutics

Semma Therapeutics

ITeos Therapeutics

Cullinan Oncology

Dyne Therapeutics

Entrada Therapeutics

Epizyme

MPM BioImpact

MPM Capital

COM:MPMCAPITAL

MPM Capital

Analysis Not Available